HealthyPhase 1NCT03817476

A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood

A Phase 1 study testing iCF1(T1) 25 milligram BI 425809, iCF2(T2) 25 milligram BI 425809 and TF2(R) 25 milligram BI 425809 in people with Healthy, run by Boehringer Ingelheim at 1 site in Germany.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The main objective of this trial is to investigate the relative bioavailability of batch 1 of the intended commercial tablet formulation (iCF1) of BI 425809 vs batch 2 of the intended commercial tablet formulation (iCF2) of BI 425809 vs BI 425809 (TF2) formulation. Read more about this study

Who is it for?: Ages 18 to 55 yearsHealthy volunteers can take part
Conditions the study is for: Healthy
What is being tested?: iCF1(T1) 25 milligram BI 425809, iCF2(T2) 25 milligram BI 425809 and TF2(R) 25 milligram BI 425809
Type of treatment: Pill or oral medicine
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 18 participants
Where: 1 siteGermany
Study dates: 11 Feb 2019to 28 May 2019
Phase: Phase 1
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 55 years
All sexes
Healthy volunteers accepted
Adult

Who may be able to join

Healthy male or female subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests
Age of 18 to 55 years (inclusive)
Body Mass Index (BMI) of 18.5 to 29.9 kg/m2 (inclusive)
Signed and dated written informed consent prior to admission to the study, in accordance with GCP and local legislation
Male subjects, or female subjects who meet any of the following criteria from at least 30 days before the first administration of trial medication until 30 days after trial completion:
Use of adequate contraception, e.g. any of the following methods plus condom:

Show all 11Show fewer

--- implants, injectables, combined oral or vaginal contraceptives, intrauterine device
Sexually abstinent
A vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)
Surgically sterilised (including hysterectomy)
Postmenopausal, defined as at least 1 year of spontaneous amenorrhea (in questionable cases a blood sample with levels of FSH above 40 U/L and estradiol below 30 ng/L is confirmatory)

Who cannot join

Any finding in the medical examination (including Blood Pressure (BP), Pulse Rate (PR) or Electrocardiogram (ECG)) deviating from normal and assessed as clinically relevant by the investigator
Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 beats per minute (bpm)
Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
Any evidence of a concomitant disease assessed as clinically relevant by the investigator
Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)

Show all 24Show fewer

Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
History of relevant orthostatic hypotension, fainting spells, or blackouts
Chronic or relevant acute infections
History of relevant allergy or hypersensitivity (including allergy to the trial medication or its excipients)
Use of drugs within 30 days of planned administration of trial medication that might reasonably influence the results of the trial (including drugs that cause QT/QTc interval prolongation)
Intake of an investigational drug in another clinical trial within 60 days of planned administration of investigational drug in the current trial, or concurrent participation in another clinical trial in which investigational drug is administered
Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
Inability to refrain from smoking on specified trial days
Alcohol abuse (consumption of more than 20 g per day for females and 30 g per day for males)
Drug abuse or positive drug screening
Blood donation of more than 100 mL within 30 days of planned administration of trial medication or intended blood donation during the trial
Intention to perform excessive physical activities within one week prior to the administration of trial medication or during the trial
Inability to comply with the dietary regimen of the trial site
A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms in males or repeatedly greater than 470 ms in females) or any other relevant Electrocardiogram (ECG) finding at screening
A history of additional risk factors for Torsade de Pointes (such as heart failure, hypokalaemia, or family history of Long QT Syndrome)
Subject is assessed as unsuitable for inclusion by the investigator, for instance, because the subject is not considered able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study
Female subjects, only: Positive pregnancy test, pregnancy, or plans to become pregnant within 30 days after study completion
Female subjects, only: Lactation

Trial locations and contacts

1 site in 1 country.

Germany1 site

Humanpharmakologisches Zentrum Biberach
Biberach, 88397

Other trials in Germany

About this study

Official title: Relative Bioavailability of Batch 1 and Batch 2 of the Intended Commercial Formulation of BI 425809 Compared to Each Other and to TF 2 Formulation of BI 425809 Following Oral Administration in Healthy Male and Female Subjects (Randomized, Open-label, Single-dose, Three-treatment, Three-period, Six-sequence Crossover Study)

Conditions: Healthy
Being tested: iCF1(T1) 25 milligram BI 425809, iCF2(T2) 25 milligram BI 425809, TF2(R) 25 milligram BI 425809

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

iCF1(T1) 25 milligram BI 425809Drug
Also called Iclepertin
One 25 milligram BI 425809 iCF1 tablet. Oral with 240 milliliter of water after an overnight fast of at least 10 hours.
iCF2(T2) 25 milligram BI 425809Drug
Also called Iclepertin
One 25 milligram BI 425809 iCF2 tablet. Oral with 240 milliliter of water after an overnight fast of at least 10 hours.
TF2(R) 25 milligram BI 425809Drug
Also called Iclepertin
One 25 milligram BI 425809 TF2 tablet. Oral with 240 milliliter of water after an overnight fast of at least 10 hours.

Study groups in NCT03817476
Study group	Role	What they receive
Treatment sequence A: TF2/iCF1/iCF2	Experimental	TF2(R):One 25 milligram (mg) BI 425809 TF2 tablet - iCF1(T1):One 25 mg BI 425809 iCF1 tablet - iCF2(T2):One 25 mg BI 425809 iCF2 tablet. All treatments: Oral with 240 milliliter of water after an overnight fast of at least 10 hours. There was a washout period of 14 days between treatments. TF=Tablet formulation, iCF=Intended commercial formulation. Receives: Drug: iCF1(T1) 25 milligram BI 425809; Drug: iCF2(T2) 25 milligram BI 425809; Drug: TF2(R) 25 milligram BI 425809
Treatment sequence B: iCF1/iCF2/TF2	Experimental	iCF1(T1):One 25 milligram (mg) BI 425809 iCF1 tablet - iCF2(T2):One 25 mg BI 425809 iCF2 tablet - TF2(R):One 25 mg BI 425809 TF2 tablet. All treatments: Oral with 240 milliliter of water after an overnight fast of at least 10 hours. There was a washout period of 14 days between treatments. Receives: Drug: iCF1(T1) 25 milligram BI 425809; Drug: iCF2(T2) 25 milligram BI 425809; Drug: TF2(R) 25 milligram BI 425809
Treatment sequence C: iCF2/TF2/iCF1	Experimental	iCF2(T2):One 25 milligram (mg) BI 425809 iCF2 tablet - TF2(R):One 25 mg BI 425809 TF2 tablet - iCF1(T1):One 25 mg BI 425809 iCF1 tablet. All treatments: Oral with 240 milliliter of water after an overnight fast of at least 10 hours. There was a washout period of 14 days between treatments. Receives: Drug: iCF1(T1) 25 milligram BI 425809; Drug: iCF2(T2) 25 milligram BI 425809; Drug: TF2(R) 25 milligram BI 425809
Treatment sequence D: TF2/iCF2/iCF1	Experimental	TF2(R):One 25 milligram (mg) BI 425809 TF2 tablet - iCF2(T2):One 25 mg BI 425809 iCF2 tablet - iCF1(T1):One 25 mg BI 425809 iCF1 tablet. All treatments: Oral with 240 milliliter of water after an overnight fast of at least 10 hours. There was a washout period of 14 days between treatments. Receives: Drug: iCF1(T1) 25 milligram BI 425809; Drug: iCF2(T2) 25 milligram BI 425809; Drug: TF2(R) 25 milligram BI 425809
Treatment sequence E: iCF1/TF2/iCF2	Experimental	iCF1(T1):One 25 milligram (mg) BI 425809 iCF1 tablet - TF2(R):One 25 mg BI 425809 TF2 tablet - iCF2(T2):One 25 mg BI 425809 iCF2 tablet. All treatments: Oral with 240 milliliter of water after an overnight fast of at least 10 hours. There was a washout period of 14 days between treatments. Receives: Drug: iCF1(T1) 25 milligram BI 425809; Drug: iCF2(T2) 25 milligram BI 425809; Drug: TF2(R) 25 milligram BI 425809
Treatment sequence F: iCF2/iCF1/TF2	Experimental	iCF2(T2):One 25 mg BI 425809 iCF2 tablet - iCF1(T1):One 25 milligram (mg) BI 425809 iCF1 tablet - TF2(R):One 25 mg BI 425809 TF2 tablet. All treatments: Oral with 240 milliliter of water after an overnight fast of at least 10 hours. There was a washout period of 14 days between treatments. Receives: Drug: iCF1(T1) 25 milligram BI 425809; Drug: iCF2(T2) 25 milligram BI 425809; Drug: TF2(R) 25 milligram BI 425809

What is being measured

The primary outcome is the main question the study is designed to answer.

Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72)
Area under the concentration-time curve of BI 425809 in plasma over the time interval from 0 to 72 hours (AUC0-72). Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) on the logarithmic scale including effects for 'sequence', 'subjects nested within sequences', 'period', and 'treatment'.
Measured: within 3 hours before and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 34, 48 and 72 hours after drug administration.
Maximum Measured Concentration of BI 425809 in Plasma (Cmax)
Cmax represents maximum measured concentration of BI 425809 in plasma. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) on the logarithmic scale including effects for 'sequence', 'subjects nested within sequences', 'period', and 'treatment'.
Measured: within 3 hours before and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 34, 48 and 72 hours after drug administration.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

11 Feb 201928 May 2019

First posted25 Jan 2019
Study start11 Feb 2019
Primary completion28 May 2019
Study completion28 May 2019

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for HealthyStudies of the same condition, open and under way.
More trials run by Boehringer IngelheimThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 1
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Crossover
Masking: None (open label)
Enrolment: 18 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT03817476
Sponsor's protocol ID: 1346-0019
Other IDs: 2018-003625-29, 2018
Status last verified: Apr 2026
First submitted: 24 Jan 2019
Last updated: 24 Apr 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No: Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1\. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: http://trials.boehringer-ingelheim.com/

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruitingPhase 1
Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast
Healthy Volunteers
RecruitingObservational study
Survey to Determine Incarcerated Persons' Views on Surrogate Decision Making
Healthy Volunteers
Active, not recruitingPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults
Healthy
Not yet recruitingObservational study
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Blood Donors, Apheresis
Recruiting
Metabolic Impact of VLCPUFA-Rich Fish Oil: A Clinical Study on Omega-3 Index Enhancement in Healthy Individuals
Fatty Acids, Omega-3, Fish Oils

All Healthy trials

Study at a glance

From the registry record, last updated by the sponsor on 24 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Relative Bioavailability of Batch 1 and Batch 2 of the Intended Commercial Formulation of BI 425809 Compared to Each Other and to TF 2 Formulation of BI 425809 Following Oral Administration in Healthy Male and Female Subjects (Randomized, Open-label, Single-dose, Three-treatment, Three-period, Six-sequence Crossover Study)
ClinicalTrials.gov ID: NCT03817476
Acronym / sponsor ID: 1346-0019
Conditions: Healthy
Phase: Phase 1
Study type: Interventional
Recruitment status: Completed
Enrolment: 18 participants (actual)
Lead sponsor: Boehringer IngelheimIndustry (pharma, biotech, devices)
Study start: 11 Feb 2019 (actual)
Primary completion: 28 May 2019 (actual)
Study completion: 28 May 2019 (actual)
First posted: 25 Jan 2019 (actual)
Results: Posted 30 Mar 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Crossover
Masking: None (open label)
Number of arms: 6

Arm	Type	Receives
Treatment sequence A: TF2/iCF1/iCF2	Experimental	Drug: iCF1(T1) 25 milligram BI 425809, Drug: iCF2(T2) 25 milligram BI 425809, Drug: TF2(R) 25 milligram BI 425809TF2(R):One 25 milligram (mg) BI 425809 TF2 tablet - iCF1(T1):One 25 mg BI 425809 iCF1 tablet - iCF2(T2):One 25 mg BI 425809 iCF2 tablet. All treatments: Oral with 240 milliliter of water after an overnight fast of at least 10 hours. There was a washout period of 14 days between treatments. TF=Tablet formulation, iCF=Intended commercial formulation.
Treatment sequence B: iCF1/iCF2/TF2	Experimental	Drug: iCF1(T1) 25 milligram BI 425809, Drug: iCF2(T2) 25 milligram BI 425809, Drug: TF2(R) 25 milligram BI 425809iCF1(T1):One 25 milligram (mg) BI 425809 iCF1 tablet - iCF2(T2):One 25 mg BI 425809 iCF2 tablet - TF2(R):One 25 mg BI 425809 TF2 tablet. All treatments: Oral with 240 milliliter of water after an overnight fast of at least 10 hours. There was a washout period of 14 days between treatments.
Treatment sequence C: iCF2/TF2/iCF1	Experimental	Drug: iCF1(T1) 25 milligram BI 425809, Drug: iCF2(T2) 25 milligram BI 425809, Drug: TF2(R) 25 milligram BI 425809iCF2(T2):One 25 milligram (mg) BI 425809 iCF2 tablet - TF2(R):One 25 mg BI 425809 TF2 tablet - iCF1(T1):One 25 mg BI 425809 iCF1 tablet. All treatments: Oral with 240 milliliter of water after an overnight fast of at least 10 hours. There was a washout period of 14 days between treatments.
Treatment sequence D: TF2/iCF2/iCF1	Experimental	Drug: iCF1(T1) 25 milligram BI 425809, Drug: iCF2(T2) 25 milligram BI 425809, Drug: TF2(R) 25 milligram BI 425809TF2(R):One 25 milligram (mg) BI 425809 TF2 tablet - iCF2(T2):One 25 mg BI 425809 iCF2 tablet - iCF1(T1):One 25 mg BI 425809 iCF1 tablet. All treatments: Oral with 240 milliliter of water after an overnight fast of at least 10 hours. There was a washout period of 14 days between treatments.
Treatment sequence E: iCF1/TF2/iCF2	Experimental	Drug: iCF1(T1) 25 milligram BI 425809, Drug: iCF2(T2) 25 milligram BI 425809, Drug: TF2(R) 25 milligram BI 425809iCF1(T1):One 25 milligram (mg) BI 425809 iCF1 tablet - TF2(R):One 25 mg BI 425809 TF2 tablet - iCF2(T2):One 25 mg BI 425809 iCF2 tablet. All treatments: Oral with 240 milliliter of water after an overnight fast of at least 10 hours. There was a washout period of 14 days between treatments.
Treatment sequence F: iCF2/iCF1/TF2	Experimental	Drug: iCF1(T1) 25 milligram BI 425809, Drug: iCF2(T2) 25 milligram BI 425809, Drug: TF2(R) 25 milligram BI 425809iCF2(T2):One 25 mg BI 425809 iCF2 tablet - iCF1(T1):One 25 milligram (mg) BI 425809 iCF1 tablet - TF2(R):One 25 mg BI 425809 TF2 tablet. All treatments: Oral with 240 milliliter of water after an overnight fast of at least 10 hours. There was a washout period of 14 days between treatments.

Who may qualify

Ages: 18 to 55 years
Sex: All
Healthy volunteers: Accepted
Age groups: Adult

Key inclusion criteria (11 listed)

Healthy male or female subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests
Age of 18 to 55 years (inclusive)
Body Mass Index (BMI) of 18.5 to 29.9 kg/m2 (inclusive)
Signed and dated written informed consent prior to admission to the study, in accordance with GCP and local legislation
Male subjects, or female subjects who meet any of the following criteria from at least 30 days before the first administration of trial medication until 30 days after trial completion:

Key exclusion criteria (24 listed)

Any finding in the medical examination (including Blood Pressure (BP), Pulse Rate (PR) or Electrocardiogram (ECG)) deviating from normal and assessed as clinically relevant by the investigator
Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 beats per minute (bpm)
Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
Any evidence of a concomitant disease assessed as clinically relevant by the investigator
Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
iCF1(T1) 25 milligram BI 425809Also: IclepertinOne 25 milligram BI 425809 iCF1 tablet. Oral with 240 milliliter of water after an overnight fast of at least 10 hours.	Drug	Treatment sequence A: TF2/iCF1/iCF2, Treatment sequence B: iCF1/iCF2/TF2, Treatment sequence C: iCF2/TF2/iCF1, Treatment sequence D: TF2/iCF2/iCF1, Treatment sequence E: iCF1/TF2/iCF2, Treatment sequence F: iCF2/iCF1/TF2
iCF2(T2) 25 milligram BI 425809Also: IclepertinOne 25 milligram BI 425809 iCF2 tablet. Oral with 240 milliliter of water after an overnight fast of at least 10 hours.	Drug	Treatment sequence A: TF2/iCF1/iCF2, Treatment sequence B: iCF1/iCF2/TF2, Treatment sequence C: iCF2/TF2/iCF1, Treatment sequence D: TF2/iCF2/iCF1, Treatment sequence E: iCF1/TF2/iCF2, Treatment sequence F: iCF2/iCF1/TF2
TF2(R) 25 milligram BI 425809Also: IclepertinOne 25 milligram BI 425809 TF2 tablet. Oral with 240 milliliter of water after an overnight fast of at least 10 hours.	Drug	Treatment sequence A: TF2/iCF1/iCF2, Treatment sequence B: iCF1/iCF2/TF2, Treatment sequence C: iCF2/TF2/iCF1, Treatment sequence D: TF2/iCF2/iCF1, Treatment sequence E: iCF1/TF2/iCF2, Treatment sequence F: iCF2/iCF1/TF2

Primary outcome

Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72)
Time frame: within 3 hours before and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 34, 48 and 72 hours after drug administration.
Area under the concentration-time curve of BI 425809 in plasma over the time interval from 0 to 72 hours (AUC0-72). Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) on the logarithmic scale including effects for 'sequence', 'subjects nested within sequences', 'period', and 'treatment'.
Maximum Measured Concentration of BI 425809 in Plasma (Cmax)
Time frame: within 3 hours before and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 34, 48 and 72 hours after drug administration.
Cmax represents maximum measured concentration of BI 425809 in plasma. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) on the logarithmic scale including effects for 'sequence', 'subjects nested within sequences', 'period', and 'treatment'.

Results and safety

Results posted to the registry on 30 Mar 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Treatment Sequence A: TF2/iCF1/iCF2	3	3
Treatment Sequence B: iCF1/iCF2/TF2	3	3
Treatment Sequence C: iCF2/TF2/iCF1	3	3
Treatment Sequence D: TF2/iCF2/iCF1	3	3
Treatment Sequence E: iCF1/TF2/iCF2	3	3
Treatment Sequence F: iCF2/iCF1/TF2	3	3

Primary outcome: Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72)

Time frame: within 3 hours before and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 34, 48 and 72 hours after drug administration.. Geometric least squares mean (Standard Error). Unit: nanomol (nmol) * hour (h) per Liter (L)

Measure	iCF1(T1) 25 Milligram BI 425809 n = 18	iCF2(T2) 25 Milligram BI 425809 n = 18	TF2(R) 25 Milligram BI 425809 n = 18
Value	7904.16 (NA)	6400.59 (NA)	7648.23 (NA)

iCF1(T1) 25 Milligram BI 425809 vs iCF2(T2) 25 Milligram BI 425809: Adjusted Geometric Mean Ratio T1/T2: 123.49 (90% CI 118.74 to 128.43)
iCF1(T1) 25 Milligram BI 425809 vs TF2(R) 25 Milligram BI 425809: Adjusted Geometric Mean Ratio T1/R: 103.35 (90% CI 99.37 to 107.48)
iCF2(T2) 25 Milligram BI 425809 vs TF2(R) 25 Milligram BI 425809: Adjusted Geometric Mean Ratio T2/R: 83.69 (90% CI 80.47 to 87.03)

Population analysed: PKS (Pharmacokinetic parameter analysis set) included all subjects in the TS (treated set) who provided at least 1 primary pharmacokinetic (PK) endpoint that was not excluded (due to a protocol deviation relevant to the evaluation of PK or due to PK non-evaluability). Descriptive and model based analyses of PK parameters were based on the PKS.

Primary outcome: Maximum Measured Concentration of BI 425809 in Plasma (Cmax)

Measure	iCF1(T1) 25 Milligram BI 425809 n = 18	iCF2(T2) 25 Milligram BI 425809 n = 18	TF2(R) 25 Milligram BI 425809 n = 18
Value	276.70 (NA)	220.87 (NA)	246.73 (NA)

iCF1(T1) 25 Milligram BI 425809 vs iCF2(T2) 25 Milligram BI 425809: Adjusted Geometric Mean Ratio T1/T2: 125.28 (90% CI 117.42 to 133.66)
iCF1(T1) 25 Milligram BI 425809 vs TF2(R) 25 Milligram BI 425809: Adjusted Geometric Mean Ratio T1/R: 112.15 (90% CI 105.11 to 119.65)
iCF2(T2) 25 Milligram BI 425809 vs TF2(R) 25 Milligram BI 425809: Adjusted Geometric Mean Ratio T2/R: 89.52 (90% CI 83.90 to 95.51)

Adverse events

Time frame: Adverse events: from the intake of trial medication till the end of the residual effect period, up to 11 days for each arm/ reporting group. All-cause mortality: Up to 20 days.. Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
iCF1(T1) 25 Milligram BI 425809	0 of 18 (0%)	2 of 18 (11.1%)	0 of 18
iCF2(T2) 25 Milligram BI 425809	0 of 18 (0%)	2 of 18 (11.1%)	0 of 18
TF2(R) 25 Milligram BI 425809	0 of 18 (0%)	5 of 18 (27.8%)	0 of 18

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related InfoLink provided by the sponsor.
Individual participant dataSharing planned: No. Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: http://trials.boehringer-ingelheim.com/

Related trials for Healthy

Not yet recruitingPhase 1
Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast
Healthy Volunteers
RecruitingObservational study
Survey to Determine Incarcerated Persons' Views on Surrogate Decision Making
Healthy Volunteers
Active, not recruitingPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults
Healthy
Not yet recruitingObservational study
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Blood Donors, Apheresis
Recruiting
Metabolic Impact of VLCPUFA-Rich Fish Oil: A Clinical Study on Omega-3 Index Enhancement in Healthy Individuals
Fatty Acids, Omega-3, Fish Oils

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing iCF1(T1) 25 milligram BI 425809, iCF2(T2) 25 milligram BI 425809 and TF2(R) 25 milligram BI 425809 in people with Healthy, run by Boehringer Ingelheim at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 30 Mar 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72) (time frame: within 3 hours before and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 34, 48 and 72 hours after drug administration.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03817476.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.